Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States

Abstract Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open forum infectious diseases Jg. 7; H. 9; S. ofaa389
Hauptverfasser:	Aslam, Saima, Lampley, Elizabeth, Wooten, Darcy, Karris, Maile, Benson, Constance, Strathdee, Steffanie, Schooley, Robert T
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	US Oxford University Press 01.09.2020
Schlagworte:	Antibiotics Bacterial infections Infections Major Phages United States > US multidrug-resistant infections bacteriophage therapy phage therapy
ISSN:	2328-8957, 2328-8957
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Abstract Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. Methods We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). Results Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. Conclusions We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. Bacteriophage therapy (BT) is an emerging therapeutic strategy against multidrug resistant infections. We demonstrate safety and successful outcome in 7/10 cases treated with intravenous BT and share lessons learned, BT referral pattern, and regulatory aspects in the US.
AbstractList	Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018.BACKGROUNDDue to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018.We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards).METHODSWe reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards).Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility.RESULTSAmong 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility.We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials.CONCLUSIONSWe demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. Bacteriophage therapy (BT) is an emerging therapeutic strategy against multidrug resistant infections. We demonstrate safety and successful outcome in 7/10 cases treated with intravenous BT and share lessons learned, BT referral pattern, and regulatory aspects in the US. Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. Methods We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). Results Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. Conclusions We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. Abstract Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. Methods We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). Results Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for Pseudomonas aeruginosa, Staphylococcus aureus, and Mycobacterium abscessus. Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. Conclusions We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials. Bacteriophage therapy (BT) is an emerging therapeutic strategy against multidrug resistant infections. We demonstrate safety and successful outcome in 7/10 cases treated with intravenous BT and share lessons learned, BT referral pattern, and regulatory aspects in the US. Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative. After the first successful case of intravenous BT to treat a systemic MDR infection at our institution in 2017, the Center for Innovative Phage Applications and Therapeutics (IPATH) was created at the University of California, San Diego, in June 2018. We reviewed IPATH consult requests from June 1, 2018, to April 30, 2020, and reviewed the regulatory process of initiating BT on a compassionate basis in the United States. We also reviewed outcomes of the first 10 cases at our center treated with intravenous BT (from April 1, 2017, onwards). Among 785 BT requests to IPATH, BT was administered to 17 of 119 patients in whom it was recommended. One-third of requests were for , , and . Intravenous BT was safe with a successful outcome in 7/10 antibiotic-recalcitrant infections at our center (6 were before IPATH). BT may be safely self-administered by outpatients, used for infection suppression/prophylaxis, and combined successfully with antibiotics despite antibiotic resistance, and phage resistance may be overcome with new phage(s). Failure occurred in 2 cases despite in vitro phage susceptibility. We demonstrate the safety and feasibility of intravenous BT for a variety of infections and discuss practical considerations that will be critical for informing future clinical trials.
Author	Schooley, Robert T Strathdee, Steffanie Lampley, Elizabeth Karris, Maile Aslam, Saima Wooten, Darcy Benson, Constance
AuthorAffiliation	2 Center for Innovative Phage Applications and Therapeutics, University of California , San Diego, La Jolla, California, USA 1 Division of Infectious Diseases and Global Public Health, University of California , San Diego, La Jolla, California, USA
AuthorAffiliation_xml	– name: 1 Division of Infectious Diseases and Global Public Health, University of California , San Diego, La Jolla, California, USA – name: 2 Center for Innovative Phage Applications and Therapeutics, University of California , San Diego, La Jolla, California, USA
Author_xml	– sequence: 1 givenname: Saima surname: Aslam fullname: Aslam, Saima email: saslam@health.ucsd.edu organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA – sequence: 2 givenname: Elizabeth surname: Lampley fullname: Lampley, Elizabeth organization: Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, La Jolla, California, USA – sequence: 3 givenname: Darcy surname: Wooten fullname: Wooten, Darcy organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA – sequence: 4 givenname: Maile surname: Karris fullname: Karris, Maile organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA – sequence: 5 givenname: Constance surname: Benson fullname: Benson, Constance organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA – sequence: 6 givenname: Steffanie surname: Strathdee fullname: Strathdee, Steffanie organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA – sequence: 7 givenname: Robert T surname: Schooley fullname: Schooley, Robert T organization: Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33005701$$D View this record in MEDLINE/PubMed
BookMark	eNp9kk1v1DAQhiNUREvpjTOyxIEeCNhxEscXJFixUGkREt2erVlnsusqa6e2s1L_Vn8hDrutSiW42JbmmdfvfLzMjqyzmGWvGf3AqOQfXWfadADwRj7LTgpeNHkjK3H06H2cnYVwTSlljFZUyBfZMeeUVoKyk-xugSE4G8gCwVtsydy7LYkbJHPjQySMklkKox6j2SGZQcBAXEcubPSwQ-vGQL6AjuiNGzawRrLcoIfhlkRHlh4hkh9jH03rx3X-C4MJEWy8T4E-CXWoo5ksJBbIpbHrPn2ENgHE2D9erqyJydtlhIjhVfa8gz7g2eE-za7mX5ez7_ni57eL2edFrishYs5RVJRJTWsGoivqUmpJedNyKMuugBJ5W7WyQo0r3dYM6xpWvFxB1wjBuW74afZprzuMqy22GqeSezV4swV_qxwY9XfEmo1au50SFZNCyCRwfhDw7mbEENXWBI19DxZT31RRlk1J66qZ0LdP0Gs3epvKU5wJKkvJ5eTozWNHD1bux5mA93tAexeCx-4BYVRNC6OmhVGHhUl48QTXJrU4DSPVY_p_Jb3bJ7lx-L_8b68s1rk
CitedBy_id	crossref_primary_10_3390_ph15121498 crossref_primary_10_3390_antibiotics10060672 crossref_primary_10_1002_phar_2828 crossref_primary_10_1093_cid_ciac453 crossref_primary_10_3390_v14112339 crossref_primary_10_1155_2024_6252415 crossref_primary_10_3390_v15041020 crossref_primary_10_1016_j_jgar_2024_07_007 crossref_primary_10_1016_j_jinf_2021_05_027 crossref_primary_10_1016_j_cmi_2021_09_027 crossref_primary_10_3390_v13101901 crossref_primary_10_1128_aac_00728_23 crossref_primary_10_1016_j_isci_2024_109790 crossref_primary_10_1016_j_tim_2021_04_008 crossref_primary_10_3389_fphar_2024_1356179 crossref_primary_10_1093_cid_ciad533 crossref_primary_10_1371_journal_ppat_1011424 crossref_primary_10_1016_j_jcot_2022_102067 crossref_primary_10_1242_dmm_049159 crossref_primary_10_3390_v14020342 crossref_primary_10_1016_j_jgar_2024_07_019 crossref_primary_10_3389_fmed_2024_1432703 crossref_primary_10_1007_s15010_024_02178_0 crossref_primary_10_1016_j_jcf_2022_09_009 crossref_primary_10_1128_mra_00333_23 crossref_primary_10_1016_j_addr_2022_114378 crossref_primary_10_1016_j_copbio_2021_02_006 crossref_primary_10_3390_antibiotics10121497 crossref_primary_10_1016_S0140_6736_25_00737_8 crossref_primary_10_1093_cid_ciad528 crossref_primary_10_1002_cpt_2214 crossref_primary_10_1128_aac_01728_23 crossref_primary_10_3390_v17010123 crossref_primary_10_1038_s41467_022_31455_5 crossref_primary_10_1080_10408398_2022_2059442 crossref_primary_10_1089_phage_2022_0010 crossref_primary_10_1146_annurev_med_080219_122208 crossref_primary_10_1371_journal_pbio_3003063 crossref_primary_10_1093_cid_ciad516 crossref_primary_10_1038_s41598_023_36034_2 crossref_primary_10_3390_ijms242115628 crossref_primary_10_1097_MCP_0000000000000864 crossref_primary_10_1371_journal_ppat_1012971 crossref_primary_10_3390_ijms242417529 crossref_primary_10_1371_journal_pbio_3001424 crossref_primary_10_3390_antibiotics9110827 crossref_primary_10_3390_microorganisms9112366 crossref_primary_10_1080_1040841X_2025_2554619 crossref_primary_10_1097_MAT_0000000000001956 crossref_primary_10_1080_13543776_2025_2545784 crossref_primary_10_3390_antibiotics9110799 crossref_primary_10_1007_s11908_022_00772_7 crossref_primary_10_1128_aem_00309_22 crossref_primary_10_1016_j_ijantimicag_2024_107372 crossref_primary_10_1172_JCI184323 crossref_primary_10_1073_pnas_2423286122 crossref_primary_10_1080_19490976_2024_2331520 crossref_primary_10_1093_jalm_jfac051 crossref_primary_10_3390_pharmaceutics14071425 crossref_primary_10_3389_fmed_2023_1199657 crossref_primary_10_3389_fmicb_2022_993990 crossref_primary_10_3390_antibiotics14060553 crossref_primary_10_3390_ph18081115 crossref_primary_10_1093_femsre_fuab040 crossref_primary_10_3390_ijerph22071139 crossref_primary_10_1093_ofid_ofad221 crossref_primary_10_1128_mbio_01822_25 crossref_primary_10_1093_femsre_fuab048 crossref_primary_10_1186_s40168_021_01026_9 crossref_primary_10_1177_20499361211053480 crossref_primary_10_1007_s40121_022_00591_2 crossref_primary_10_3390_antibiotics12040751 crossref_primary_10_1128_aac_00037_23 crossref_primary_10_2147_IJN_S453566 crossref_primary_10_1002_smll_202308814 crossref_primary_10_1016_j_cmi_2023_02_006 crossref_primary_10_1128_mra_00664_22 crossref_primary_10_1016_j_healun_2022_01_018 crossref_primary_10_3390_antibiotics12030502 crossref_primary_10_1016_j_jmb_2023_168058 crossref_primary_10_1093_jpids_piab012 crossref_primary_10_3390_v16111800 crossref_primary_10_1007_s00408_024_00700_7 crossref_primary_10_1016_j_jddst_2025_107484 crossref_primary_10_1016_j_cmi_2023_06_001 crossref_primary_10_1097_MOT_0000000000001029 crossref_primary_10_3390_v16030478 crossref_primary_10_3390_ph15020177 crossref_primary_10_1016_j_chom_2024_09_004 crossref_primary_10_3390_antibiotics10111337 crossref_primary_10_1371_journal_pbio_3002566 crossref_primary_10_1002_eji_202451543 crossref_primary_10_1016_j_coviro_2022_101290 crossref_primary_10_3389_fphar_2021_699054 crossref_primary_10_3390_antibiotics12121684 crossref_primary_10_1016_j_mimet_2021_106346 crossref_primary_10_3389_fmicb_2022_796132 crossref_primary_10_3390_antibiotics10040435 crossref_primary_10_1097_INF_0000000000004000 crossref_primary_10_1042_EBC20240024 crossref_primary_10_1042_EBC20240020 crossref_primary_10_3389_fmicb_2024_1372325 crossref_primary_10_1016_j_cmicom_2025_105135 crossref_primary_10_3390_v13071206 crossref_primary_10_1038_s41591_021_01403_9 crossref_primary_10_3390_pathogens11070777 crossref_primary_10_1016_j_ijantimicag_2025_107570 crossref_primary_10_1038_s41467_024_53146_z crossref_primary_10_1172_JCI187996 crossref_primary_10_1016_j_glmedi_2023_100042 crossref_primary_10_3390_pathogens13050424 crossref_primary_10_3389_fmicb_2025_1614697 crossref_primary_10_3390_biomedicines11102860 crossref_primary_10_1128_aem_01353_24 crossref_primary_10_1007_s10096_021_04296_1 crossref_primary_10_1128_cmr_00044_24 crossref_primary_10_1089_phage_2023_0034 crossref_primary_10_1128_AAC_01879_21 crossref_primary_10_3390_ph14010034 crossref_primary_10_1016_j_ejphar_2025_177511 crossref_primary_10_3390_v16091348 crossref_primary_10_3390_pharmaceutics16030374 crossref_primary_10_1089_phage_2021_0018 crossref_primary_10_3389_fmicb_2020_599906 crossref_primary_10_1016_j_isci_2022_104372 crossref_primary_10_3390_v13102049 crossref_primary_10_3390_v14010033 crossref_primary_10_3390_v15051210 crossref_primary_10_1128_msphere_00345_22 crossref_primary_10_3389_fmed_2022_1040457 crossref_primary_10_3390_v17081080 crossref_primary_10_1161_JAHA_121_023080 crossref_primary_10_3390_ijms24044038 crossref_primary_10_1093_cid_ciad481 crossref_primary_10_1183_23120541_00367_2021 crossref_primary_10_1186_s13099_025_00735_y crossref_primary_10_3390_microorganisms12020253 crossref_primary_10_3389_fmicb_2020_609017 crossref_primary_10_3390_v13061182 crossref_primary_10_1038_s41598_024_53276_w crossref_primary_10_3390_biom15081182 crossref_primary_10_1016_j_cell_2022_11_017 crossref_primary_10_1111_apm_13455 crossref_primary_10_1016_j_jss_2021_10_010 crossref_primary_10_1128_spectrum_03221_23 crossref_primary_10_3390_antibiotics10060627 crossref_primary_10_1016_j_micres_2025_128231 crossref_primary_10_1128_aac_02071_21 crossref_primary_10_1128_Spectrum_00497_21 crossref_primary_10_3390_antibiotics11101310 crossref_primary_10_1128_aac_00578_23 crossref_primary_10_3390_antibiotics10050556 crossref_primary_10_1016_j_jinf_2024_106125 crossref_primary_10_3390_antibiotics14010002 crossref_primary_10_1007_s15010_021_01675_w crossref_primary_10_1080_21645515_2023_2175519 crossref_primary_10_1183_16000617_0121_2022 crossref_primary_10_3390_v13061057 crossref_primary_10_3390_v13122414 crossref_primary_10_3390_v16071051 crossref_primary_10_1111_jam_15647 crossref_primary_10_1016_j_coviro_2021_12_003 crossref_primary_10_1016_S1473_3099_24_00424_9 crossref_primary_10_1186_s13568_025_01837_1 crossref_primary_10_3390_pathogens10091100 crossref_primary_10_3390_v15030721 crossref_primary_10_1016_j_jcf_2025_03_669 crossref_primary_10_3390_ph14111157 crossref_primary_10_1016_j_virusres_2021_198406 crossref_primary_10_3389_fbrio_2023_1231657 crossref_primary_10_1093_cid_ciad335 crossref_primary_10_1128_iai_00065_23 crossref_primary_10_1016_j_copbio_2021_03_002 crossref_primary_10_1097_MCP_0000000000000764 crossref_primary_10_1016_j_jddst_2025_107173 crossref_primary_10_1128_spectrum_02874_22 crossref_primary_10_3390_v13091785 crossref_primary_10_1097_MCP_0000000000001050 crossref_primary_10_1021_acscentsci_5c00562 crossref_primary_10_7554_eLife_73679 crossref_primary_10_1016_j_medj_2023_07_002 crossref_primary_10_1128_jvi_01113_24 crossref_primary_10_3390_v15081736 crossref_primary_10_1016_j_ijmm_2025_151668 crossref_primary_10_1002_phar_2806 crossref_primary_10_1093_ofid_ofad051 crossref_primary_10_1128_spectrum_01477_23 crossref_primary_10_3390_idr16060092 crossref_primary_10_1038_s41564_024_01705_x crossref_primary_10_47183_mes_2023_060 crossref_primary_10_15252_emmm_202012435 crossref_primary_10_1016_S0140_6736_24_02081_6 crossref_primary_10_3389_fmicb_2021_741304 crossref_primary_10_1002_ski2_93 crossref_primary_10_1016_j_chroma_2025_465890 crossref_primary_10_1038_s41467_025_60598_4 crossref_primary_10_3390_antibiotics11101340 crossref_primary_10_1002_mco2_70280 crossref_primary_10_1038_s41598_021_86571_x crossref_primary_10_1093_ofid_ofac194 crossref_primary_10_1016_j_cmi_2023_10_018 crossref_primary_10_1038_s41467_024_47192_w crossref_primary_10_3390_antibiotics12050842 crossref_primary_10_3390_ph16101347 crossref_primary_10_1128_msystems_00218_21 crossref_primary_10_1016_j_cell_2022_04_024 crossref_primary_10_3390_ph14111162 crossref_primary_10_2147_IDR_S341265 crossref_primary_10_3390_antibiotics13100919
Cites_doi	10.1128/AAC.00954-17 10.1007/s15010-019-01319-0 10.1038/s41564-019-0666-4 10.1093/ofid/ofy064 10.1016/j.healun.2019.01.001 10.1038/s41426-018-0169-z 10.1128/AAC.01987-19 10.1111/ajt.15503 10.4161/bact.21440 10.1016/j.chom.2015.10.013 10.1007/978-1-60327-164-6_7 10.1016/j.mib.2019.03.005
ContentType	Journal Article
Copyright	The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2020 The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2020 – notice: The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. – notice: The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1093/ofid/ofaa389
DatabaseName	Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Publicly Available Content Database PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2328-8957
ExternalDocumentID	PMC7519779 33005701 10_1093_ofid_ofaa389 10.1093/ofid/ofaa389
Genre	Journal Article
GeographicLocations	United States--US
GeographicLocations_xml	– name: United States--US
GrantInformation_xml	– fundername: ;
GroupedDBID	0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX 7X7 8C1 8FI 8FJ AAYXX ABEJV ABGNP ABUWG ACUHS AFFHD AFKRA AMNDL BENPR CCPQU CITATION FYUFA HMCUK IHR ITC PHGZM PHGZT PIMPY PJZUB PPXIY UKHRP NPM 3V. 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c577t-3e75019c061a7f2649c9038d3a44f2a4e3d5d95ecebcd61e66ab34baf87733c83
IEDL.DBID	8C1
ISICitedReferencesCount	218
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000593127000047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2328-8957
IngestDate	Tue Nov 04 01:55:13 EST 2025 Thu Sep 04 17:08:07 EDT 2025 Tue Oct 07 07:29:07 EDT 2025 Wed Feb 19 02:27:11 EST 2025 Sat Nov 29 01:54:25 EST 2025 Tue Nov 18 22:18:26 EST 2025 Wed Aug 28 03:17:32 EDT 2024
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	multidrug-resistant infections bacteriophage therapy phage therapy
Language	English
License	This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com http://creativecommons.org/licenses/by-nc-nd/4.0 The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c577t-3e75019c061a7f2649c9038d3a44f2a4e3d5d95ecebcd61e66ab34baf87733c83
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://www.proquest.com/docview/3170949398?pq-origsite=%requestingapplication%
PMID	33005701
PQID	3170949398
PQPubID	7089189
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_7519779 proquest_miscellaneous_2448406589 proquest_journals_3170949398 pubmed_primary_33005701 crossref_primary_10_1093_ofid_ofaa389 crossref_citationtrail_10_1093_ofid_ofaa389 oup_primary_10_1093_ofid_ofaa389
PublicationCentury	2000
PublicationDate	2020-09-01
PublicationDateYYYYMMDD	2020-09-01
PublicationDate_xml	– month: 09 year: 2020 text: 2020-09-01 day: 01
PublicationDecade	2020
PublicationPlace	US
PublicationPlace_xml	– name: US – name: United States – name: Oxford
PublicationTitle	Open forum infectious diseases
PublicationTitleAlternate	Open Forum Infect Dis
PublicationYear	2020
Publisher	Oxford University Press
Publisher_xml	– name: Oxford University Press
References	Green (2020101307150101800_CIT0001) 2019 Henry (2020101307150101800_CIT0003) 2012; 2 Schooley (2020101307150101800_CIT0012) 2020; 5 Kropinski (2020101307150101800_CIT0004) 2009; 501 Law (2020101307150101800_CIT0008) 2019; 47 LaVergne (2020101307150101800_CIT0009) 2018; 5 Torres-Barceló (2020101307150101800_CIT0005) 2018; 7 Segall (2020101307150101800_CIT0010) 2019; 51 Schooley (2020101307150101800_CIT0002) 2017; 61 Aslam (2020101307150101800_CIT0006) 2019; 19 Aslam (2020101307150101800_CIT0007) 2019 Secor (2020101307150101800_CIT0011) 2015; 18 Aslam (2020101307150101800_CIT0013) 2019; 64
References_xml	– volume: 61 start-page: e00954-17 year: 2017 ident: 2020101307150101800_CIT0002 article-title: Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00954-17 – volume: 47 start-page: 665 year: 2019 ident: 2020101307150101800_CIT0008 article-title: Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient publication-title: Infection doi: 10.1007/s15010-019-01319-0 – volume: 5 start-page: 391 year: 2020 ident: 2020101307150101800_CIT0012 article-title: Treat phage like living antibiotics publication-title: Nat Microbiol doi: 10.1038/s41564-019-0666-4 – volume: 5 start-page: XXX–XX year: 2018 ident: 2020101307150101800_CIT0009 article-title: Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection publication-title: Open Forum Infect Dis doi: 10.1093/ofid/ofy064 – year: 2019 ident: 2020101307150101800_CIT0007 article-title: Novel bacteriophage therapy for treatment of left ventricular assist device infection publication-title: J Heart Lung Transplant doi: 10.1016/j.healun.2019.01.001 – volume: 7 start-page: 168 year: 2018 ident: 2020101307150101800_CIT0005 article-title: The disparate effects of bacteriophages on antibiotic-resistant bacteria publication-title: Emerg Microbes Infect doi: 10.1038/s41426-018-0169-z – volume: 64 start-page: e01987-19 year: 2019 ident: 2020101307150101800_CIT0013 article-title: What’s old is new again: bacteriophage therapy in the 21st century publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01987-19 – volume: 19 start-page: 2631 year: 2019 ident: 2020101307150101800_CIT0006 article-title: Early clinical experience of bacteriophage therapy in 3 lung transplant recipients publication-title: Am J Transplant doi: 10.1111/ajt.15503 – volume: 2 start-page: 159 year: 2012 ident: 2020101307150101800_CIT0003 article-title: Development of a high throughput assay for indirectly measuring phage growth using the OmniLog™ system publication-title: Bacteriophage doi: 10.4161/bact.21440 – volume: 18 start-page: 549 year: 2015 ident: 2020101307150101800_CIT0011 article-title: Filamentous bacteriophage promote biofilm assembly and function publication-title: Cell Host Microbe doi: 10.1016/j.chom.2015.10.013 – start-page: 485 volume-title: Encyclopedia of Microbiology year: 2019 ident: 2020101307150101800_CIT0001 article-title: Phage therapy – volume: 501 start-page: 69 year: 2009 ident: 2020101307150101800_CIT0004 article-title: Enumeration of bacteriophages by double agar overlay plaque assay publication-title: Methods Mol Biol doi: 10.1007/978-1-60327-164-6_7 – volume: 51 start-page: 46 year: 2019 ident: 2020101307150101800_CIT0010 article-title: Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy publication-title: Curr Opin Microbiol doi: 10.1016/j.mib.2019.03.005
SSID	ssj0001105079
Score	2.5831559
Snippet	Abstract Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an... Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic alternative.... Background Due to increasing multidrug-resistant (MDR) infections, there is an interest in assessing the use of bacteriophage therapy (BT) as an antibiotic... Bacteriophage therapy (BT) is an emerging therapeutic strategy against multidrug resistant infections. We demonstrate safety and successful outcome in 7/10...
SourceID	pubmedcentral proquest pubmed crossref oup
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	ofaa389
SubjectTerms	Antibiotics Bacterial infections Infections Major Phages
Title	Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States
URI	https://www.ncbi.nlm.nih.gov/pubmed/33005701 https://www.proquest.com/docview/3170949398 https://www.proquest.com/docview/2448406589 https://pubmed.ncbi.nlm.nih.gov/PMC7519779
Volume	7
WOSCitedRecordID	wos000593127000047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: TOX dateStart: 20140101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 7X7 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: BENPR dateStart: 20140401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 8C1 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2328-8957 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: PIMPY dateStart: 20140401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYhtBe-B4URnVI8ISiJXUSO0-IVauoxEo1ilSeIscfrNKWlCTdH8ZfyNlxuxYJeOAlUpRLcpJ_vvv5fL4j5A1NC5OqUAehDBMbrZIBN0oHseGScsloIYVrNsEmEz6fZ1MfcGt8WuXaJjpDrSppY-Qn6OdwJZLRjL9f_ghs1yi7u-pbaOyRg2gQxnZi8mF0G2NB8hCyzOe749r9BAdM4UUIavu6b3mindNtWyTz91zJLeczevC_aj8k9z3thA8dTh6RO7p8TO6d-431J-TnJ7R4CEBw9Va1glFdXQOSQxgtkB9CFIJt7anlyppHGKLva6AyMLbq3rg6r3DaFX6ulpdoo2DWlSuAtoKZJabgjvqqevU9uNCNZa1lu34FNRv7pDBUAWUFfEGXeoU_siVDa1iUTpeOIENHkJ-Sr6Oz2fBj4Ns5BDJhrA2oRnYSZRIZhGAGiVgms5ByRUUcm4GINVWJyhItdSFVGuk0FQWNC2E4Y5RKTo_IflmV-jmBJFWxwJdDo1XMdYEkywgeF1ImIk4i0yPv1kObS1_r3LbcuMq7PXeaWyDkHgg98nYjvexqfPxBDhAl_xA5XsMg98agyW8x0COvN49xGtu9GVFqHKIcWRYutZEO4ieedYjb_IjalgIsjHqE7WBxI2BLhO8-KReXrlQ4s-eSWfbi72q9JIcDG0ZwqXPHZL-tV_oVuStv2kVT98kemzN35X03v_rk4PRsMr3ouwAG3k3H59NveDf7PP8FLbo6Ig
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEF6VgoAL70egwCDRE7JqZ23v-oAQFKJGTSMEQcrNrPdBIxU7OE4Rf4oDv5AZP9IECTj1wMUXj-3V-tuZb3dnv2HsGY8zFxvfer72I1qt0p50xnqhk5pLLXimVV1sQozHcjpN3m2xH91ZGEqr7Hxi7ahNoWmNfA_jHM5EEp7Il_OvHlWNot3VroRGA4tD-_0bTtkWL4Zv8P_u9vuDt5P9A6-tKuDpSIjK4xaDZJBoDGRKOOQDiU58Lg1XYej6KrTcRCaJrLaZNnFg41hlPMyUk0JwriXH915gF9GPC0ohE1NxtqaDZMUXSZtf7yd8DwFi8KIUpzrya5Fv4zTdGqn9PTdzLdgNrv9v3XSDXWtpNbxqxsFNtmXzW-zyUZs4cJv9HKFHxwEGtZ6sNTAoiy-A5BcGM-S_EPhApUutXpL7h32M7QsoHAype05rHVt43QhbF_Nj9MEwaeQYoCpgQsQb6qPMplx-9t7bBbHyvOoewZYN26Q3bALaKviAlOEEP0SSqCXM8rotzQQAmgnAHfbxXHrsLtvOi9zeZxDFJlT4sO-sCaXNkEQ6JcNM60iFUeB67HkHpVS3Wu5UUuQkbXIKeErAS1vg9djuynreaJj8wQ4Qlf8w2elgl7bObpGeYa7Hnq5uo5uivSeVW_xFKbJIGRLdxVfcaxC--hCnkgnCD3pMbGB_ZUAS6Jt38tlxLYUu6Ny1SB78vVlP2JWDydEoHQ3Hhw_Z1T4tmdRpgjtsuyqX9hG7pE-r2aJ8XI9nYJ_Oe2T8AukAkI0
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lessons+Learned+From+the+First+10+Consecutive+Cases+of+Intravenous+Bacteriophage+Therapy+to+Treat+Multidrug-Resistant+Bacterial+Infections+at+a+Single+Center+in+the+United+States&rft.jtitle=Open+forum+infectious+diseases&rft.au=Aslam%2C+Saima&rft.au=Lampley%2C+Elizabeth&rft.au=Wooten%2C+Darcy&rft.au=Karris%2C+Maile&rft.date=2020-09-01&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=7&rft.issue=9&rft_id=info:doi/10.1093%2Fofid%2Fofaa389&rft.externalDocID=10.1093%2Fofid%2Fofaa389
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon